Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27693760 | 0.62 | TRPA1 (0.39) | — | |
| SCHEMBL25765754 | 0.61 | — | — | |
| Ammonia Solution, Strong SCHEMBL28016359 | 0.61 | TRPA1 (0.38) | — | |
| SCHEMBL2590797 | 0.61 | PDK2 (0.46) | GABRA1GABRB2TAAR1HTR1ACRHBP | |
| Iodide SCHEMBL2594068 | 0.58 | PDK2 (0.43) | GABRA1GABRB2TAAR1HTR1ACRHBP | |
| SCHEMBL12142036 | 0.58 | GABRA1 (0.48) | GABRA1GABRB2CRHBPCRHR2 | |
| SCHEMBL25425763 | 0.57 | GABRA1 (0.58) | GABRA1GABRB2 | |
| SCHEMBL36294 | 0.57 | GABRA1 (0.58) | GABRA1GABRB2 | |
| SCHEMBL29390847 | 0.57 | GABRA1 (0.58) | GABRA1GABRB2 | |
| SCHEMBL599099 | 0.56 | GABRA1 (0.57) | GABRA1GABRB2TAAR1HTR1APDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006034196-A1 | COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR | LIFELIKE BIOMATIC INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | LIFELIKE BIOMATIC, INC. (US) | 2006-03-23 | — | — | US | claimed |
| WO-2006034196-A1 | COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR | LIFELIKE BIOMATIC INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | LIFELIKE BIOMATIC, INC. (US) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | GRIN1, GRIN3A, GRIN2A | GABRA1 34/4885GABRB2 44/4885TAAR1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.